- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case C-452/14: Judgment of the Court (Third Chamber) of 1 October 2015 (request for a preliminary ruling from the Consiglio di Stato — Italy) — Agenzia Italiana del Farmaco (AIFA), Ministero della Salute v Doc Generici Srl (Reference for a preliminary ruling — Article 267 TFEU — Obligation to bring the matter before the Court of Justice — Approximation of laws — Proprietary medicinal products — Medicinal products for human use — Marketing authorisation — Variation — Fees — Regulation (EC) No 297/95 — Regulation (EC) No 1234/2008 — Scope)
ECLI:EU:UNKNOWN:62014CA0452
62014CA0452
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
16.11.2015
Official Journal of the European Union
C 381/11
(Case C-452/14) (<span class="super">1</span>)
((Reference for a preliminary ruling - Article 267 TFEU - Obligation to bring the matter before the Court of Justice - Approximation of laws - Proprietary medicinal products - Medicinal products for human use - Marketing authorisation - Variation - Fees - Regulation (EC) No 297/95 - Regulation (EC) No 1234/2008 - Scope))
(2015/C 381/12)
Language of the case: Italian
Referring court
Parties to the main proceedings
Applicants: Agenzia Italiana del Farmaco (AIFA), Ministero della Salute
Defendant: Doc Generici Srl
Operative part of the judgment
1)Neither Council Regulation (EC) No 297/95 of 10 February 1995 on fees payable to the European Agency for the Evaluation of Medicinal Products, as amended by Commission Regulation (EU) No 273/2012 of 27 March 2012, nor Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products, as amended by Commission Regulation (EU) No 712/2012 of 3 August 2012, requires a competent national authority to demand, in respect of the change of address of a marketing authorisation holder, payment of as many charges as there are marketing authorisations requiring variation, and nor do those regulations prohibit such an authority from demanding such payment.
2)Article 267 TFEU must be interpreted as meaning that a court or tribunal against whose decisions there is no judicial remedy under national law is required, in circumstances such as those in the main proceedings, to comply with its obligation to bring the matter before the Court of Justice.
(<span class="note">1</span>) OJ C 448, 15.12.2014.